Europe
In its CRL, the FDA identified concerns regarding the impact of patch-site adhesion on efficacy and indicated the need for patch modifications.
In June, it dosed its first two patients using a novel therapeutic, AMT-130, delivered directly to the brain. Initial readouts are expected in a year’s time.
Russia’s minister of health, Mikhail Murashko, indicated that the country plans a nationwide program to vaccinate its population against COVID-19 starting in October.
Eight months after inking a collaboration deal, MorphoSys and Incyte won approval for Monjuvi for adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 3, 2020.
As usual, there was plenty of clinical trial news last week. Here’s a look.
GlaxoSmithKline and Sanofi struck a $2.1 billion deal with the U.S. government’s Operation Warp Speed program to supply an initial 100 million doses of a COVID-19 vaccine candidate under development by the two companies.
Genomic medicine company Sangamo Therapeutics announced today that it has entered a global licensing collaboration agreement with Novartis to develop and commercialize gene regulation therapies for three neurodevelopmental targets, including autism spectrum disorder.
Biopharma and life science companies strengthen their leadership teams and board with these Movers & Shakers.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
PRESS RELEASES